Cancer News and Research

Latest Cancer News and Research

TSRI chemists develop correct structure of highly promising anticancer compound

Chemists at The Scripps Research Institute (TSRI) have determined the correct structure of a highly promising anticancer compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials in cancer patients.

20 May 2014

Biovision provides list of businesses, projects selected for Investor Conference and Catalyzer sessions

Biovision, the annual forum on future-oriented research in life sciences, today announces the list of biotech and medtech companies and projects selected for the Investor Conference and Catalyzer sessions. Awards will be presented during the closing ceremony.

20 May 2014

Scientists uncover early steps of totipotency in sperm precursors

In the body, a skin cell will always be skin, and a heart cell will always be heart. But in the first hours of life, cells in the nascent embryo become totipotent: they have the incredible flexibility to mature into skin, heart, gut, or any type of cell.

20 May 2014

MILabs presents Advanced Imaging Scientist award to Prof. David Townsend

MILabs BV is proud to announce that the Advanced Imaging Scientist award 2014 will be presented to Prof. Dr. David William Townsend for his groundbreaking scientific contribution to diagnose cancer at the Utrecht Life Science seminar on May 19th 2014.

20 May 2014

IL-8 expression predicts lung adenocarcinoma prognosis

Interleukin -8 expression is associated with a poor lung adenocarcinoma prognosis, say Japanese researchers, especially in patients whose tumours are positive for the KRAS mutation.

19 May 2014

CTR1 may be required for successful platinum-based therapy in NSCLC

Tumours with undetectable levels of the copper transporter CTR1 have a significantly reduced response to platinum-based chemotherapy for non-small-cell lung cancer, study findings indicate.

19 May 2014

Vandetanib delays disease progression in elderly NSCLC patients

Vandetanib used in combination with gemcitabine significantly improves progression-free survival compared with gemcitabine alone when used as a first-line treatment for elderly patients with advanced non-small-cell lung cancer, Italian researchers report.

19 May 2014

SUVmax predicts outcome in advanced NSCLC

Parameters measured by positron emission tomography with integrated computed tomography at diagnosis can be used to predict outcome following concurrent chemoradiotherapy for stage III non-small-cell lung cancer, research shows.

19 May 2014

HRQoL changes predict survival in NSCLC

Changes in health-related quality of life during treatment may help predict survival in patients with advanced non-small-cell lung cancer, suggest findings from the EORTC 08975 study.

19 May 2014

Researchers identify drugs to slow progression of idiopathic pulmonary fibrosis

Researchers in separate clinical trials found two drugs slow the progression of idiopathic pulmonary fibrosis, a fatal lung disease with no effective treatment or cure, and for which there is currently no therapy approved by the Food and Drug Administration.

19 May 2014

DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

RNA interference (RNAi) is a naturally occurring process, which cells can use to silence, or ‘turn off’ unwanted genes.

From Quest Diagnostics 19 May 2014

IFRC, IFPMA launch '4 Healthy Habits' initiative to combat noncommunicable diseases

The International Federation of Red Cross and Red Crescent Societies (IFRC) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) launch today, during a side event at the 67th World Health Assembly, a global initiative, called '4 Healthy Habits'.

19 May 2014

CCHIT awards 2014 ONC HIT Certification to Mirth Connect version 3.0.1

Mirth, LLC, a wholly owned subsidiary of Quality Systems, Inc. and a global leader in health information technology, announced today that Mirth® Connect version 3.0.1 is compliant with the ONC 2014 Edition criteria and was certified as an Electronic Health Record (EHR) Module on May 1, 2014 by the Certification Commission for Health Information Technology (CCHIT®), an ONC-ACB, in accordance with the applicable Eligible Providers (Ambulatory) certification criteria adopted by the Secretary of Health and Human Services.

19 May 2014

University of New Mexico scientist wins prestigious C-Change Comprehensive Cancer Control Champion Award

University of New Mexico Cancer Center scientist Barbara Damron, RN, PhD, FAAN, recently won the prestigious C-Change Comprehensive Cancer Control Champion Award.

19 May 2014

Cancer Council urges Queenslanders to get to know their own skin

Cancer Council is urging Queenslanders to get to know their own skin and stay vigilant about early detection, with reports of misdiagnosis for some types of melanoma in the Australasian Journal of Dermatology.

19 May 2014

Registration now open for interactive one day workshop for GPs

Registration is now open for an interactive one day workshop in Brisbane, designed by GPs for GPs, that will cover five hot topics — including statin prescribing and whether the hype is justified on newer oral anticoagulants.

19 May 2014

Study to investigate use of OCT in collaboration with Melanoma Institute of Australia

Michelson Diagnostics, the UK based medical device company focused on multi-beam Optical Coherence Tomography ('OCT') technology, has commenced a clinical study to investigate the use of OCT to diagnose basal cell carcinoma in collaboration with the Melanoma Institute of Australia using Michelson's Diagnostics VivoSight system.

19 May 2014

FibroGen’s Phase 2a study supports safety and efficacy of FG-3019 in IPF patients

FibroGen, Inc. (FibroGen) announced today the presentation of clinical data at the American Thoracic Society (ATS) International Conference supporting the safety and efficacy of FG-3019 in patients with idiopathic pulmonary fibrosis (IPF), a debilitating and life-threatening lung disease for which there is currently no approved therapy in the United States.

19 May 2014

Low risk prostate cancer not always low risk

More and more men who believe they have low-risk prostate cancers are opting for active surveillance, forgoing treatment and monitoring the cancer closely with prostate-specific antigen (PSA) tests, digital rectal exams and ultrasounds at regular intervals to see if their tumors are growing. Nearly 400 men are now enrolled in the UCLA Active Surveillance program, the largest in Southern California.

19 May 2014

Dogs accurately detect prostate cancer

With an accuracy rating of 98 percent, specially-trained dogs were able to smell volatile organic compounds (VOCs) released into urine by prostate tumors, setting the stage for a potentially new means of early prostate cancer detection.

19 May 2014